Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery

Drugs
R Davis, R Whittington

Abstract

Patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) experience transient haemostatic defects as a result of adverse changes to their blood components, blood cells and specific coagulation proteins. Aprotinin is a naturally occurring serine protease inhibitor isolated from bovine lung tissue which inhibits kallikrein and plasmin. A high dose aprotinin regimen (aprotinin 280mg loading dose over 20 to 30 minutes after anaesthesia induction followed by 70 mg/h for the duration of the operation and 280mg added to the priming fluid of the CPB circuit) has been used during CPB in order to reduce perioperative bleeding. Recent clinical trials confirm the efficacy of high dose aprotinin in reducing blood loss and transfusion requirements associated with primary cardiac procedures such as coronary artery bypass graft (CABG) or heart valve replacement surgery. High dose aprotinin is also effective in procedures known to possess a high risk for excessive blood loss, such as repeat CABG or heart valve replacement surgery, cardiac surgery in patients with infective endocarditis, or in patients receiving aspirin (acetylsalicylic acid) before surgery. Studies indicate that low dose aprotinin (280mg added to CPB pump prime flu...Continue Reading

Citations

Oct 10, 1997·Anesthesia and Analgesia·C J O'ConnorK J Tuman
May 19, 2006·Pathophysiology of Haemostasis and Thrombosis·Simone FlightPaul Masci
Dec 6, 2001·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·P D Raymond, N A Marsh
Mar 26, 2008·Journal of Cardiothoracic Surgery·Efstratios ApostolakisDimitrios Dougenis
May 2, 1997·The Journal of Biological Chemistry·K A DelariaP P Tamburini
Mar 7, 2001·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·R A CardiganM J Gallimore
Jan 25, 2003·Vox Sanguinis·T Kovesi, D Royston
Mar 1, 1997·Anesthesia and Analgesia·P RobbinsD Royston
Nov 20, 1998·Biological Chemistry·C P VioA A Jaffa
Nov 22, 2001·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·M A BedirhanO Taşçi
Nov 4, 2000·Expert Opinion on Investigational Drugs·S D DunbarL R Zacharski
Jun 13, 2000·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·M Al DouriR Borum Andreasen
May 5, 2021·Scientific Reports·Eun-Jung SongJeong-Ki Kim
Aug 14, 1999·Biochimica Et Biophysica Acta·A Pellegrini, R von Fellenberg
Feb 12, 2000·Journal of Medicinal Chemistry·D LeungD P Fairlie
May 1, 1997·Journal of Cardiothoracic and Vascular Anesthesia·D Royston
Jan 26, 2005·Thrombosis Research·Hyoung-Min KangWayne L Chandler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.